
DNA X, Inc.
SONM·NASDAQ
Last updated as of 2026-03-11 05:13 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
SONM stock price change
On the last trading day, SONM stock closed at 4.64 USD, with a price change of 0.00% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreSONM key data
Previous close4.64 USD
Market cap6.91M USD
Volume1.70K
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-177.67 USD
Net income (FY)−33.65M USD
Revenue (FY)58.30M USD
Next report dateMar 23, 2026
EPS estimate10.980 USD
Revenue estimate41.21M USD USD
Shares float945.11K
Beta (1Y)−0.25

DNA X, Inc. overview
DNA X, Inc. engages in the provision of rugged and consumer durable mobile devices including phones and accessories designed to provide extra protection for users that demand more durability. It operates through the following geographical segments: the United States, Canada and Latin America, Europe and Middle East, and Asia Pacific. The company was founded by Ram Chandran, Isaac Eteminan, Anush Gopalan, Jai Kumar, Sudu Srinivasan, and Joakim Wiklund on August 5, 1999 and is headquartered in San Diego, CA.
Sector
Electronic technology
Industry
Telecommunications Equipment
CEO
Michael C. Mulica
Headquarters
San Diego
Website
sonimtech.com
Founded
1999
Employees (FY)
160
Change (1Y)
+68 +73.91%
Revenue / Employee (1Y)
364.36K USD
Net income / Employee (1Y)
−210.30K USD
SONM stock price forecast
According to technical indicators for SONM stock, the price is likely to fluctuate within the range of 5.10–5.30 USD over the next week. Market analysts predict that the price of SONM stock will likely fluctuate within the range of 3.82–7.31 USD over the next months.
Based on 1-year price forecasts from 19 analysts, the highest estimate is 8.99 USD, while the lowest estimate is 5.86 USD.
For more information, please see the
SONM stock price forecast
page.
Latest SONM stock news
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Finviz2026-03-04 22:03:44
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:22:06
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:25:25
Life Sciences Tools & Services Stocks Q4 Overview: Comparing 10x Genomics (NASDAQ:TXG) With Its Competitors
101 finance2026-03-06 22:57:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Finviz2026-03-09 11:03:47
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Korro Announces Oversubscribed $85 Million Private Placement
Finviz2026-03-09 11:33:52
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Finviz2026-03-09 12:48:57
Should You Consider Purchasing, Retaining, or Selling Tempus AI Shares as 2026 Approaches?
101 finance2026-03-09 14:04:53
3 Lucrative Stocks with Unresolved Issues
101 finance2026-03-09 16:06:13
3 Lucrative Stocks That Still Raise Some Questions
101 finance2026-03-09 16:06:13
Networking now 30% of HPE revenue but over half of profits
Finviz2026-03-10 17:04:05
Rivian’s R2 Debut in the First Half of 2026 May Be the Key Test That Validates or Challenges Its Volume Advantage
101 finance2026-03-10 17:40:18
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Finviz2026-03-04 22:03:44
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:22:06
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:25:25
Life Sciences Tools & Services Stocks Q4 Overview: Comparing 10x Genomics (NASDAQ:TXG) With Its Competitors
101 finance2026-03-06 22:57:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
